文献速递类风湿关节炎

托法替布体外调节类风湿关节炎患者水痘-带状疱疹病毒特异性CD4+ T细胞免疫应答

Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

本研究探讨托法替布对类风湿关节炎(RA)患者水痘-带状疱疹病毒(VZV)特异性T细胞免疫应答的体外影响。结果显示托法替布以剂量依赖方式显著降低VZV特异性CD4+ T细胞的IFNγ产生、增殖、活化及CXCR3表达,提示其调节Th1应答,可能解释RA患者VZV特异性细胞免疫应答不佳。

要点

  • 托法替布剂量依赖性抑制VZV特异性CD4+ T细胞的IFNγ产生和增殖。
  • 托法替布降低VZV特异性CD4+ T细胞活化标志CD69和趋化因子受体CXCR3表达。
  • 托法替布不影响VZV特异性CD4+ T细胞亚群分布及穿孔素、颗粒酶B表达。

核心结论

  • 托法替布在体外显著调节RA患者VZV特异性CD4+ T细胞的Th1应答。

研究设计与样本

  • 体外研究,比较RA患者与健康供者淋巴细胞经VZV抗原刺激后,托法替布对VZV特异性CD4+ T细胞免疫应答的影响。

主要发现

  • 托法替布以剂量依赖方式显著降低VZV特异性CD4+ T细胞的IFNγ产生、增殖、活化及CXCR3表达。
  • 托法替布对VZV特异性CD4+ T细胞的naive、效应或记忆亚群分布无影响。
  • 托法替布对VZV特异性CD4+ T细胞的穿孔素或颗粒酶B表达无影响。

临床怎么用

  • RA患者VZV特异性细胞免疫应答不佳,可考虑用于制定增强VZV特异性Th1应答的疫苗接种策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: RA is a chronic inflammatory disease characterized by lymphocyte infiltration and release of inflammatory cytokines. Previous studies have shown that treatment with Janus kinase inhibitors, such as tofacitinib, increased the incidence rate of herpes zoster compared with conventional DMARDs. Therefore, this study aimed to investigate the effect of tofacitinib on the varicella-zoster-virus (VZV)-specific T cell immune response. METHODS: The effect of tofacitinib on the VZV-specific T cell immune response was determined by evaluating the IFNγ production, the proliferative capacity, the VZV-induced differentiation into effector and memory T cells, the expression of activation marker CD69 and helper T cell type 1 (Th1)-characteristic chemokine receptors, such as CXCR3 and CCR5, as well as cytotoxic activity (perforin and granzyme B expression) of CD4+ T cells of patients with RA compared with healthy donors upon stimulation with VZV antigen in vitro. RESULTS: Tofacitinib significantly reduced the IFNγ production, proliferation, activation, and CXCR3 expression of VZV-specific CD4+ T cells in a dose-dependent manner in short- and long-term lymphocyte culture. No effect on the distribution of naive, effectors or memory, or on the expression of perforin or granzyme B by VZV-specific CD4+ T cells was observed. CONCLUSION: This study showed that tofacitinib significantly modulated the Th1 response to VZV. The poor VZV-specific cellular immune response in patients with RA may be considered in recommendations regarding appropriate vaccination strategies for enhancing the VZV-specific Th1 response.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Almanzar G, Kienle F, Schmalzing M, et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2019. PMID: 31106368. doi:10.1093/rheumatology/kez175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。